CNS Disorders
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock global CNS disorder market insights. Stay ahead on neurodegenerative diseases, psychiatry, and neurology drug development for strategic pharma investment.
Showing 1–10 of 10 articles
Quick answer
NovaPharmaNews CNS Disorders hub for FDA covers 10 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Opinion: How the military may be fueling eating disorders in men
Axsome Therapeutics Receives FDA Approval for AUVELITY to Treat Alzheimer's Agitation - First-in-Class Breakthrough
FDA Places Clinical Hold on Newron's Evenamide Phase III Trial for Treatment-Resistant Schizophrenia
GLP-1 Eating Disorder Risk: What You Need to Know
FDA Approves RGEN-101: RareGen’s Orphan Drug for Genetic Disorder
FDA Approves Synapton: Breakthrough for Severe Alzheimer's Treatment
FDA Approves Kresladi: First Gene Therapy for Rare Immune Disorder LAD-I Marks Medical Breakthrough
FDA Approves CogniMax: New Early-Stage Alzheimer's Treatment
FDA Approves Altuviiio: Sanofi's Long-Acting Hemophilia A Therapy
FDA Approves Ztalmy: First Therapy for CDKL5 Deficiency Seizures
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.